Aspira pathlab & Diagnostics Limited has announced the resignation of its Company Secretary cum Compliance Officer, marking a significant change in the company's key managerial personnel. The announcement was made through a formal disclosure to BSE Limited on March 07, 2026, in compliance with regulatory requirements.

Key Personnel Change Details

Ms. Krupali Shah, holding Membership No: A70473, has tendered her resignation from the position of Company Secretary cum Compliance Officer due to personal reasons. The resignation has been accepted by the company's Board of Directors and will become effective from March 08, 2026.

Regulatory Compliance

The company has fulfilled its disclosure obligations pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made to BSE Limited, where the company's shares are listed under Security Code 540788 and Security ID ASPIRA.

In her formal resignation letter to the Board of Directors, Ms. Shah expressed gratitude for the support and cooperation extended during her tenure with the company. She specifically confirmed that there are no other material reasons for her resignation beyond those mentioned in her letter.

Administrative Formalities

The resignation letter was received and accepted by the company, with Executive Director Nikunj Mange signing the acceptance on behalf of Aspira Pathlab & Diagnostics Limited. Ms. Shah has requested the company to file necessary forms with the Registrar of Companies, Ministry of Corporate Affairs to formalize her resignation.

The company's disclosure follows the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, ensuring complete transparency regarding changes in key managerial personnel. This resignation represents a routine corporate governance matter handled in accordance with established regulatory frameworks.

Aspira pathlab & Diagnostics Limited announced its unaudited standalone financial results for the third quarter and nine months ended December 31, 2025, showing mixed performance with quarterly losses offset by nine-month profitability. The Mumbai-based diagnostics company's Board of Directors approved the results at a meeting held on February 10, 2026.

Q3FY26 Financial Performance

The company reported a significant quarterly loss, marking a sharp reversal from the previous year's performance. Total expenses exceeded income, leading to operational challenges during the quarter.

Nine-Month Performance Analysis

Despite quarterly challenges, the company maintained profitability for the nine-month period, though at reduced levels compared to the previous year. Revenue growth was positive, but margin compression affected overall profitability.

Expense Structure and Cost Analysis

The company's expense structure showed significant increases across multiple categories during Q3FY26. Employee benefits expense rose to ₹245.07 lakhs from ₹196.57 lakhs in Q3FY25, while other expenses increased substantially to ₹240.79 lakhs from ₹160.07 lakhs year-on-year.

Key expense components for Q3FY26 included:

• Cost of materials consumed: ₹112.19 lakhs
• Laboratory testing charges: ₹34.86 lakhs
• Finance costs: ₹9.81 lakhs
• Depreciation and amortisation: ₹38.23 lakhs

Corporate Developments

The Board of Directors approved a material related party transaction between the company and Yashraj Research Foundation for sale of services worth ₹5 crores, subject to member approval. This transaction requires shareholder consent as per regulatory requirements.

Regulatory Compliance and Governance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors in compliance with SEBI LODR Regulations, 2015. The results underwent limited review by statutory auditors Sarda Soni Associates LLP, who provided an unmodified opinion. The company maintains a paid-up equity share capital of ₹1,029.30 lakhs with face value of ₹10 per share.

The company noted the impact of new labour codes notified by the Government of India in November 2025, resulting in an increase in gratuity liability of ₹12 lakhs disclosed under employee benefits expenses.